Replies to post #225387 on Biotech Values

[DewDiligence]

ABBV—Seems like an overreaction, but: i) Nobody saw this deal coming, so there’s more of a kneejerk sell-off impulse than in a typical large merger; and ii) Few investors truly understand how great a global franchise Botox is (#msg-147281766).